Industries > Pharma > Allergy Immunotherapy Market Report to 2031
Allergy Immunotherapy Market Report to 2031
Forecasts by Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT) (Tablets and Drops)), By Allergy Type (Pollens, House Dust Mites, Mould, Animal Dander, Bee Venom, Cockroaches/Insects, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) PLUS COVID-19 Recovery Scenarios
Allergy Immunotherapy Market – our new study reveals trends, R&D progress, and predicted revenues
Where is the Allergy Immunotherapy market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 500+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Allergy Immunotherapy Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Allergy Immunotherapy Market: By Treatment Type
• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
o Tablets
o Drops
Allergy Immunotherapy Market: By Allergy Type
• Pollens
• House Dust Mites
• Mould
• Animal Dander
• Bee Venom
• Cockroaches/Insects
• Others
Allergy Immunotherapy Market: By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Allergy Immunotherapy Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Allergy Immunotherapy Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Allergy Immunotherapy Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Allergy Immunotherapy Market, with forecasts for Treatment Type, Allergy Type, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Allergy Immunotherapy market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Allergy Immunotherapy Market. Some of the company’s profiled in this report include ASIT Biotech, Circassia, Mylan N.V., Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer plc, Allergy Therapeutics, ALK-Abelló A/S, DESENTUM OY, HAL Allergy B.V., HollisterStier Allergy, LETIPharma, and DBV Technologies SA.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Allergy Immunotherapy Market Report to 2031: Forecasts by Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT) (Tablets and Drops)), By Allergy Type (Pollens, House Dust Mites, Mould, Animal Dander, Bee Venom, Cockroaches/Insects, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Allergy Immunotherapy Market
2.1. Allergy Immunotherapy Market Definition
2.2. Treatment Type Submarkets Definitions
2.3. Allergy Type Submarkets Definitions
2.4. Distribution Channel Submarkets Definitions
3. Allergy Immunotherapy Market Overview
3.1. Global Allergy Immunotherapy Market Size and Forecast by Region
3.2. Global Allergy Immunotherapy Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rise in the prevalence of allergic disorders
3.3.1.2. Technological advancements in sublingual dosage formulations
3.3.1.3. Presence for strong product pipeline
3.3.1.4. Launch of new sublingual immunotherapies in emerging economies will drive the growth of the market
3.3.1.5. Major players are introducing several allergen immunotherapy tablets (AITs) in potential markets
3.3.1.6. Increase in risk factors causing allergies
3.3.1.7. Rising screening for allergy and reimbursement scenario
3.3.2. Market Restraints/Challenges
3.3.2.1. Drawbacks associated with the use of allergy immunotherapy
3.3.2.2. Restricted healthcare spending in underserved market of Europe will restrain the growth
3.3.3. Opportunities
3.3.3.1. Allergy immune therapies will be launched in the U.S.
3.3.4. Global Allergy Immunotherapy Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Allergy Immunotherapy Market Analysis and Forecast 2021-2031, by Treatment Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Subcutaneous Immunotherapy (SCIT)
4.1.2. Sublingual Immunotherapy (SLIT)
4.1.2.1. Tablets
4.1.2.2. Drops
5. Global Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 by Allergy Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Pollens
5.1.2. House Dust Mites
5.1.3. Mould
5.1.4. Animal Dander
5.1.5. Bee Venom
5.1.6. Cockroaches/Insects
5.1.7. Others
6. Global Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospital Pharmacy
6.1.2. Retail Pharmacy
6.1.3. Online Pharmacy
7. North America Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Allergy Immunotherapy Market Size and Forecast by Treatment Type
7.3. North America Allergy Immunotherapy Market Size and Forecast by Allergy Type
7.4. North America Allergy Immunotherapy Market Size and Forecast by Distribution Channel
7.5. U.S. Allergy Immunotherapy Market
7.6. Canada Allergy Immunotherapy Market
8. Europe Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Allergy Immunotherapy Market Size and Forecast by Treatment Type
8.3. Europe Allergy Immunotherapy Market Size and Forecast by Allergy Type
8.4. Europe Allergy Immunotherapy Market Size and Forecast by Distribution Channel
8.5. UK Allergy Immunotherapy Market
8.6. Germany Allergy Immunotherapy Market
8.7. France Allergy Immunotherapy Market
8.8. Rest of Europe Allergy Immunotherapy Market
9. Asia Pacific Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Allergy Immunotherapy Market Size and Forecast by Treatment Type
9.3. Asia Pacific Allergy Immunotherapy Market Size and Forecast by Allergy Type
9.4. Asia Pacific Allergy Immunotherapy Market Size and Forecast by Distribution Channel
9.5. China Allergy Immunotherapy Market
9.6. India Allergy Immunotherapy Market
9.7. Japan Allergy Immunotherapy Market
9.8. Rest of Asia Pacific Allergy Immunotherapy Market
10. Latin America Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Allergy Immunotherapy Market Size and Forecast by Treatment Type
10.3. Latin America Allergy Immunotherapy Market Size and Forecast by Allergy Type
10.4. Latin America Allergy Immunotherapy Market Size and Forecast by Distribution Channel
10.4.1. Brazil Allergy Immunotherapy Market
10.4.2. Mexico Allergy Immunotherapy Market
10.4.3. Rest of Latin America Allergy Immunotherapy Market
11. MEA Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Allergy Immunotherapy Market Size and Forecast by Treatment Type
11.3. MEA Allergy Immunotherapy Market Size and Forecast by Allergy Type
11.4. MEA Allergy Immunotherapy Market Size and Forecast by Distribution Channel
11.5. GCC Allergy Immunotherapy Market
11.6. South Africa Allergy Immunotherapy Market
11.7. Rest of MEA Allergy Immunotherapy Market
12. Companies in the Allergy Immunotherapy Market
12.1. ASIT Biotech
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Circassia
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. Mylan N.V.
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Adamis Pharmaceuticals Corporation
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. Merck KGaA
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Stallergenes Greer plc
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Allergy Therapeutics
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. ALK-Abelló A/S
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. DESENTUM OY
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. HAL Allergy B.V.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Allergy Immunotherapy Market Drivers & Restraints 2020
Table 7 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 13 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 37 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 38 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 39 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 40 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 41 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 42 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 43 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 44 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 45 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 46 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 47 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 48 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 49 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 50 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 51 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 52 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 53 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 54 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 55 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 56 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 57 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 58 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 59 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 60 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 61 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 62 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 63 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 64 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 65 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 66 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 67 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 68 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 69 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 70 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 71 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 72 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 73 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 74 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 75 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 76 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 77 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 78 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 79 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 80 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 81 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241 Leading 10 Allergy Immunotherapy Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 242 ASIT Biotech Profile 2019 (CEO, HQ, Founded, Website)
Table 243 ASIT Biotech Allergy Immunotherapy Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 244 ASIT Biotech Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 245 Circassia Profile 2019 (CEO, HQ, Founded, Website)
Table 246 Circassia Allergy Immunotherapy Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 247 Circassia Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 248 Mylan N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 249 Mylan N.V. Allergy Immunotherapy Selected Recent Contracts 2017-2019 (Date, Contract Treatment Type, Details)
Table 250 Mylan N.V. Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 251 Adamis Pharmaceuticals Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 252 Adamis Pharmaceuticals Corporation Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 253 Adamis Pharmaceuticals Corporation Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 254 Merck KGaA Profile 2019 (CEO, HQ, Founded, Website)
Table 255 Merck KGaA Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 256 Merck KGaA Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 257 Stallergenes Greer plc Profile 2019 (CEO, HQ, Founded, Website)
Table 258 Stallergenes Greer plc Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 259 Stallergenes Greer plc Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 260 Allergy Therapeutics Profile 2019 (CEO, HQ, Founded, Website)
Table 261 Allergy Therapeutics Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 262 Allergy Therapeutics Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 263 ALK-Abelló A/S Profile 2019 (CEO, HQ, Founded, Website)
Table 264 ALK-Abelló A/S Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 265 ALK-Abelló A/S Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 266 DESENTUM OY Profile 2019 (CEO, HQ, Founded, Website)
Table 267 DESENTUM OY Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 268 DESENTUM OY Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 269 HAL Allergy B.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 270 HAL Allergy B.V. Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 271 HAL Allergy B.V. Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 272 Other Companies Involved in the Allergy Immunotherapy Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Allergy Immunotherapy Market By Treatment Type Overview
Figure 2 Allergy Immunotherapy Market By Allergy Type Overview
Figure 3 Allergy Immunotherapy Market By Distribution Channel Overview
Figure 4 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 5 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 6 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 7 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 8 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 9 Allergy Immunotherapy Market Drivers & Restraints 2020
Figure 10 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 11 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 12 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 13 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 14 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 15 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 16 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 17 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 18 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 19 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 20 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 21 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 22 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 23 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 24 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 25 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 26 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 27 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 28 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 29 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 30 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 31 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 32 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 33 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 34 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 35 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 36 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 37 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 38 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 39 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 40 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 41 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 42 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 43 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 44 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 45 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 46 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 47 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 48 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 49 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 50 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 51 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 52 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 53 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 54 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 55 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 56 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 57 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 58 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 59 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 60 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 61 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 62 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 63 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 64 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 65 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 66 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 67 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 68 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 69 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 70 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 71 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 72 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 73 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 74 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 75 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 76 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 77 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 78 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 79 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 80 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 81 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 82 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 83 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 84 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 85 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 86 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 87 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 88 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 89 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 90 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 91 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 92 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 93 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 94 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 95 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 96 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 97 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 98 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 99 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 100 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 101 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 102 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 103 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 104 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 105 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 106 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 107 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 108 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 109 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 110 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 111 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 112 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 113 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 114 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 115 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 116 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 117 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 118 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 119 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 120 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 121 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 122 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 123 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 124 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 125 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 126 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 127 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 128 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 129 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 130 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 131 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 132 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 133 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 134 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 135 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 136 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 137 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 138 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 139 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 140 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 141 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 142 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 143 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 144 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 145 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 146 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 147 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 148 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 149 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 150 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 151 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 152 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 153 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 154 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 155 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 156 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 157 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 158 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 159 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 160 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 161 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 162 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 163 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 164 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 165 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 166 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 167 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 168 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 169 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 170 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 171 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 172 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 173 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 174 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 175 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 176 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 177 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 178 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 179 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 180 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 181 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 182 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 183 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 184 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 185 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 186 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 187 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 188 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 189 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 190 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 191 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 192 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 193 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 194 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 195 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 196 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 197 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 198 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 199 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 200 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 201 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 202 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 203 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 204 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 205 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 206 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 207 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 208 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 209 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 210 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 211 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 212 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 213 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 214 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 215 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 216 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 217 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 218 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 219 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 220 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 221 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 222 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 223 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 224 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 225 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 226 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 227 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 228 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 229 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 230 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 231 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 232 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 233 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 234 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 235 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 236 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 237 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 238 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 239 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 240 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 241 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 242 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 243 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Allergy Immunotherapy Market
2.1. Allergy Immunotherapy Market Definition
2.2. Treatment Type Submarkets Definitions
2.3. Allergy Type Submarkets Definitions
2.4. Distribution Channel Submarkets Definitions
3. Allergy Immunotherapy Market Overview
3.1. Global Allergy Immunotherapy Market Size and Forecast by Region
3.2. Global Allergy Immunotherapy Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rise in the prevalence of allergic disorders
3.3.1.2. Technological advancements in sublingual dosage formulations
3.3.1.3. Presence for strong product pipeline
3.3.1.4. Launch of new sublingual immunotherapies in emerging economies will drive the growth of the market
3.3.1.5. Major players are introducing several allergen immunotherapy tablets (AITs) in potential markets
3.3.1.6. Increase in risk factors causing allergies
3.3.1.7. Rising screening for allergy and reimbursement scenario
3.3.2. Market Restraints/Challenges
3.3.2.1. Drawbacks associated with the use of allergy immunotherapy
3.3.2.2. Restricted healthcare spending in underserved market of Europe will restrain the growth
3.3.3. Opportunities
3.3.3.1. Allergy immune therapies will be launched in the U.S.
3.3.4. Global Allergy Immunotherapy Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Allergy Immunotherapy Market Analysis and Forecast 2021-2031, by Treatment Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Subcutaneous Immunotherapy (SCIT)
4.1.2. Sublingual Immunotherapy (SLIT)
4.1.2.1. Tablets
4.1.2.2. Drops
5. Global Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 by Allergy Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Pollens
5.1.2. House Dust Mites
5.1.3. Mould
5.1.4. Animal Dander
5.1.5. Bee Venom
5.1.6. Cockroaches/Insects
5.1.7. Others
6. Global Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospital Pharmacy
6.1.2. Retail Pharmacy
6.1.3. Online Pharmacy
7. North America Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Allergy Immunotherapy Market Size and Forecast by Treatment Type
7.3. North America Allergy Immunotherapy Market Size and Forecast by Allergy Type
7.4. North America Allergy Immunotherapy Market Size and Forecast by Distribution Channel
7.5. U.S. Allergy Immunotherapy Market
7.6. Canada Allergy Immunotherapy Market
8. Europe Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Allergy Immunotherapy Market Size and Forecast by Treatment Type
8.3. Europe Allergy Immunotherapy Market Size and Forecast by Allergy Type
8.4. Europe Allergy Immunotherapy Market Size and Forecast by Distribution Channel
8.5. UK Allergy Immunotherapy Market
8.6. Germany Allergy Immunotherapy Market
8.7. France Allergy Immunotherapy Market
8.8. Rest of Europe Allergy Immunotherapy Market
9. Asia Pacific Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Allergy Immunotherapy Market Size and Forecast by Treatment Type
9.3. Asia Pacific Allergy Immunotherapy Market Size and Forecast by Allergy Type
9.4. Asia Pacific Allergy Immunotherapy Market Size and Forecast by Distribution Channel
9.5. China Allergy Immunotherapy Market
9.6. India Allergy Immunotherapy Market
9.7. Japan Allergy Immunotherapy Market
9.8. Rest of Asia Pacific Allergy Immunotherapy Market
10. Latin America Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Allergy Immunotherapy Market Size and Forecast by Treatment Type
10.3. Latin America Allergy Immunotherapy Market Size and Forecast by Allergy Type
10.4. Latin America Allergy Immunotherapy Market Size and Forecast by Distribution Channel
10.4.1. Brazil Allergy Immunotherapy Market
10.4.2. Mexico Allergy Immunotherapy Market
10.4.3. Rest of Latin America Allergy Immunotherapy Market
11. MEA Allergy Immunotherapy Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Allergy Immunotherapy Market Size and Forecast by Treatment Type
11.3. MEA Allergy Immunotherapy Market Size and Forecast by Allergy Type
11.4. MEA Allergy Immunotherapy Market Size and Forecast by Distribution Channel
11.5. GCC Allergy Immunotherapy Market
11.6. South Africa Allergy Immunotherapy Market
11.7. Rest of MEA Allergy Immunotherapy Market
12. Companies in the Allergy Immunotherapy Market
12.1. ASIT Biotech
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Circassia
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. Mylan N.V.
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Adamis Pharmaceuticals Corporation
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. Merck KGaA
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Stallergenes Greer plc
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Allergy Therapeutics
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. ALK-Abelló A/S
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. DESENTUM OY
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. HAL Allergy B.V.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Allergy Immunotherapy Market Drivers & Restraints 2020
Table 7 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 13 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 37 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 38 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 39 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 40 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 41 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 42 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 43 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 44 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 45 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 46 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 47 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 48 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 49 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 50 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 51 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 52 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 53 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 54 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 55 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 56 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 57 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 58 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 59 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 60 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 61 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 62 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 63 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 64 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 65 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 66 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 67 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 68 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 69 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 70 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 71 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 72 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 73 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 74 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 75 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 76 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 77 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 78 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 79 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 80 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 81 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241 Leading 10 Allergy Immunotherapy Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 242 ASIT Biotech Profile 2019 (CEO, HQ, Founded, Website)
Table 243 ASIT Biotech Allergy Immunotherapy Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 244 ASIT Biotech Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 245 Circassia Profile 2019 (CEO, HQ, Founded, Website)
Table 246 Circassia Allergy Immunotherapy Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 247 Circassia Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 248 Mylan N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 249 Mylan N.V. Allergy Immunotherapy Selected Recent Contracts 2017-2019 (Date, Contract Treatment Type, Details)
Table 250 Mylan N.V. Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 251 Adamis Pharmaceuticals Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 252 Adamis Pharmaceuticals Corporation Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 253 Adamis Pharmaceuticals Corporation Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 254 Merck KGaA Profile 2019 (CEO, HQ, Founded, Website)
Table 255 Merck KGaA Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 256 Merck KGaA Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 257 Stallergenes Greer plc Profile 2019 (CEO, HQ, Founded, Website)
Table 258 Stallergenes Greer plc Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 259 Stallergenes Greer plc Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 260 Allergy Therapeutics Profile 2019 (CEO, HQ, Founded, Website)
Table 261 Allergy Therapeutics Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 262 Allergy Therapeutics Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 263 ALK-Abelló A/S Profile 2019 (CEO, HQ, Founded, Website)
Table 264 ALK-Abelló A/S Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 265 ALK-Abelló A/S Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 266 DESENTUM OY Profile 2019 (CEO, HQ, Founded, Website)
Table 267 DESENTUM OY Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 268 DESENTUM OY Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 269 HAL Allergy B.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 270 HAL Allergy B.V. Allergy Immunotherapy Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 271 HAL Allergy B.V. Allergy Immunotherapy Product Offering (Segment, Product Offerings)
Table 272 Other Companies Involved in the Allergy Immunotherapy Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Allergy Immunotherapy Market By Treatment Type Overview
Figure 2 Allergy Immunotherapy Market By Allergy Type Overview
Figure 3 Allergy Immunotherapy Market By Distribution Channel Overview
Figure 4 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 5 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 6 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 7 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 8 Allergy Immunotherapy Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 9 Allergy Immunotherapy Market Drivers & Restraints 2020
Figure 10 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 11 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 12 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 13 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 14 Allergy Immunotherapy Submarket Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 15 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 16 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 17 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 18 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 19 Subcutaneous Immunotherapy (SCIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 20 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 21 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 22 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 23 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 24 Sublingual Immunotherapy (SLIT) Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 25 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 26 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 27 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 28 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 29 Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 30 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 31 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 32 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 33 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 34 Pollens Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 35 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 36 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 37 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 38 House Dust Mites Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 39 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 40 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 41 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 42 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 43 Mould Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 44 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 45 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 46 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 47 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 48 Animal Dander Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 49 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 50 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 51 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 52 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 53 Bee Venom Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 54 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 55 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 56 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 57 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 58 Cockroaches/Insects Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 59 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 60 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 61 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 62 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 63 Other Allergy Types Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 64 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 65 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 66 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 67 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 68 Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 69 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 70 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 71 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 72 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 73 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 74 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 75 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 76 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 77 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 78 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 79 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 80 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 81 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 82 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 83 Online Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 84 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 85 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 86 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 87 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 88 Regional Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 89 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 90 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 91 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 92 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 93 North America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 94 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 95 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 96 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 97 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 98 North America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 99 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 100 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 101 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 102 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 103 North America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 104 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 105 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 106 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 107 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 108 North America Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 109 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 110 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 111 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 112 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 113 US Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 114 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 115 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 116 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 117 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 118 Canada Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 119 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 120 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 121 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 122 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 123 Europe Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 124 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 125 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 126 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 127 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 128 Europe Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 129 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 130 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 131 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 132 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 133 Europe Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 134 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 135 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 136 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 137 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 138 Europe Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 139 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 140 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 141 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 142 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 143 UK Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 144 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 145 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 146 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 147 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 148 Germany Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 149 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 150 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 151 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 152 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 153 France Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 154 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 155 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 156 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 157 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 158 Rest of Europe Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 159 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 160 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 161 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 162 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 163 Asia Pacific Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 164 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 165 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 166 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 167 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 168 Asia Pacific Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 169 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 170 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 171 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 172 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 173 Asia Pacific Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 174 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 175 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 176 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 177 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 178 Asia Pacific Allergy Immunotherapy Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 179 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 180 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 181 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 182 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 183 China Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 184 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 185 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 186 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 187 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 188 India Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 189 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 190 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 191 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 192 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 193 Japan Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 194 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 195 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 196 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 197 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 198 RoAPAC Allergy Immunotherapy Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 199 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 200 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 201 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 202 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 203 Middle East Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 204 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 205 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 206 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 207 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 208 Middle East Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 209 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 210 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 211 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 212 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 213 Middle East Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 214 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 215 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 216 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 217 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 218 Latin America Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 219 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 220 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 221 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 222 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 223 Latin America Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 224 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 225 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 226 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 227 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 228 Latin America Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 229 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 230 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 231 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 232 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 233 Africa Allergy Immunotherapy Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 234 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 235 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 236 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 237 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 238 Africa Allergy Immunotherapy Market Forecast by Allergy Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 239 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 240 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 241 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 242 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 243 Africa Allergy Immunotherapy Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Companies Profiled in the Report
1. ASIT Biotech
2. Circassia
3. Mylan N.V.
4. Adamis Pharmaceuticals Corporation
5. Merck KGaA
6. Stallergenes Greer plc
7. Allergy Therapeutics
8. ALK-Abelló A/S
9. DESENTUM OY
10. HAL Allergy B.V.
11. HollisterStier Allergy
12. LETIPharma
13. DBV Technologies SA
List of Companies Mentioned in the Report:
1. Shionogi & Co.
2. Shanghai Fosun Pharmaceutical
3. Stada Arzneimittel
4. Lundbeck
5. Zhejiang International
6. Lupin
7. Taisho Pharmaceutical
8. Tasly Pharmaceutical
9. Ipsen
10. Sino Biopharmaceutical
11. Ono Pharmaceutical
12. Aurobindo
13. Cipla
14. Johnson & Johnson
15. Roche
16. Novartis
17. Sanofi
18. Bayer
19. Merck & Co. (MSD)
20. Eli Lilly
21. Astrazeneca
22. Teva
23. CR Pharmaceutical
24. Bristol-Myers Squibb
25. Merck (KGaA)
26. Novo Nordisk
27. Takeda
28. Allergan
29. Astellas Pharma
30. Mylan
31. Otsuka
32. Daiichi Sankyo
33. Valeant Pharmaceuticals
34. UCB
35. Zoetis
36. Eisai
37. Chugai Pharmaceutical
38. Perrigo
39. Sun Pharmaceutical
40. Mitsubishi Tanabe Pharma
41. Sichuan Languang Development
42. Sumitomo Dainippon Pharma
43. Yunnan Baiyao
44. Aspen Pharmacare
45. Endo
46. Kangmei Pharmaceutical
47. Galenica
48. Guangzhou Baiyunshan Pharmaceutical
49. Kyowa Hakko Kirin
50. Mallinckrod
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
1. ASIT Biotech
2. Circassia
3. Mylan N.V.
4. Adamis Pharmaceuticals Corporation
5. Merck KGaA
6. Stallergenes Greer plc
7. Allergy Therapeutics
8. ALK-Abelló A/S
9. DESENTUM OY
10. HAL Allergy B.V.
11. HollisterStier Allergy
12. LETIPharma
13. DBV Technologies SA
List of Companies Mentioned in the Report:
1. Shionogi & Co.
2. Shanghai Fosun Pharmaceutical
3. Stada Arzneimittel
4. Lundbeck
5. Zhejiang International
6. Lupin
7. Taisho Pharmaceutical
8. Tasly Pharmaceutical
9. Ipsen
10. Sino Biopharmaceutical
11. Ono Pharmaceutical
12. Aurobindo
13. Cipla
14. Johnson & Johnson
15. Roche
16. Novartis
17. Sanofi
18. Bayer
19. Merck & Co. (MSD)
20. Eli Lilly
21. Astrazeneca
22. Teva
23. CR Pharmaceutical
24. Bristol-Myers Squibb
25. Merck (KGaA)
26. Novo Nordisk
27. Takeda
28. Allergan
29. Astellas Pharma
30. Mylan
31. Otsuka
32. Daiichi Sankyo
33. Valeant Pharmaceuticals
34. UCB
35. Zoetis
36. Eisai
37. Chugai Pharmaceutical
38. Perrigo
39. Sun Pharmaceutical
40. Mitsubishi Tanabe Pharma
41. Sichuan Languang Development
42. Sumitomo Dainippon Pharma
43. Yunnan Baiyao
44. Aspen Pharmacare
45. Endo
46. Kangmei Pharmaceutical
47. Galenica
48. Guangzhou Baiyunshan Pharmaceutical
49. Kyowa Hakko Kirin
50. Mallinckrod
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
Download sample pages
Complete the form below to download your free sample pages for Allergy Immunotherapy Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Allergy Immunotherapy Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
